Pharma and BioTech Daily

Epizode

• 
  FDA Fast-Tracks NASH Drug | Pharma and Biotech Daily 17.08.2026 4min

  Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into some of the latest breakthroughs, regulatory updates, and clinical trial results shaping our industry. Recently, a significant milestone has been achieved in gene therapy. A new study showcases a groundbreaking approach to treating rare genetic disorders using CRISPR-Cas9 technology. This innovative method involves directly editing genes wi...
• 
  AstraZeneca's Baxfendy Setback: Pricing Woes | Pharma and Biotech Daily 14.08.2026 4min

  Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent weeks have showcased a dynamic landscape in these sectors, marked by scientific breakthroughs, regulatory updates, and strategic business decisions that are collectively reshaping the future of drug development and patient care. AstraZeneca recently faced challenges with its new blood pressure medication, Baxfendy, as it did not meet the cost-effectivene...
• 
  Akeso's Ivonescimab Wins NSCLC Approval in China | Pharma and Biotech Daily 13.08.2026 5min

  Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of compelling stories that underscore the dynamic shifts and groundbreaking progress within the industry. Recently, Akeso's ivonescimab received a landmark approval for first-line treatment of non-small cell lung cancer (NSCLC) in China. This marks a significant shift in China's regulatory environment, which is increasingly fo...
• 
  Bristol Myers Squibb's $2.3B Texas Investment Boosts Jobs | Pharma and Biotech Daily 12.08.2026 5min

  Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the dynamic landscape of drug manufacturing, regulatory affairs, and scientific breakthroughs that are shaping the future of patient care and therapeutic innovation. Bristol Myers Squibb has made headlines with its substantial $2.3 billion investment in a new manufacturing campus in Houston. This strategic move aims to significantly bolster...
• 
  Novo Nordisk & AWS Partner for AI Drug Discovery Breakthrough | Pharma and Biotech Daily 11.08.2026 5min

  Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a landscape marked by remarkable scientific breakthroughs, strategic alliances, and regulatory milestones that are shaping the future of healthcare. Novo Nordisk is making waves with its new partnership with Amazon Web Services, utilizing artificial intelligence to accelerate drug discovery for chronic diseases. By integrating cloud com...
• 
  Replimune's FDA Win: Tudriqev Approved After 2 Rejections | Pharma and Biotech Daily 10.08.2026 5min

  Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today's episode delves into the latest innovations and strategic shifts propelling the industry forward. A notable dialogue emerging in psychiatric drug development comes from TLDR Biotech's engagement with Shlomi Raz and Ken Belotsky, co-founders of Palomar Labs. This conversation heralds a transformative shift in psychiatric treatments, moving beyond traditio...
• 
  Moderna mRNA Flu Vaccine Approved by FDA | Pharma and Biotech Daily 07.08.2026 4min

  Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're delving into a series of pivotal advancements that underscore the dynamic nature of our industry. Starting with Moderna, which has recently secured FDA approval for its mRNA-based influenza vaccine, MFLUSIVA. This marks a monumental leap in leveraging mRNA technology beyond its initial role in COVID-19 vaccine development. The approval not only hig...
• 
  Eli Lilly's $23B Q2 Revenue Breaks Records | Pharma and Biotech Daily 06.08.2026 4min

  Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the intricate web of scientific advancements, regulatory updates, and strategic maneuvers shaping the industry. Let's begin with Eli Lilly's impressive financial performance, clocking a record-breaking $23 billion in revenue for Q2 2023. This achievement, driven by the success of Mounjaro and Zepbound in metabolic diseases, underscores the ...
• 
  Otsuka's Voyxact Shines in Phase 3 Trial | Pharma and Biotech Daily 05.08.2026 4min

  Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the latest scientific advancements, regulatory milestones, and strategic business maneuvers shaping the industry. One of the standout developments comes from Otsuka with their drug Voyxact, which has shown promising results in stabilizing kidney function decline in patients with immunoglobulin A nephropathy (IgAN). In a Phase 3 ...
• 
  Supernus & Indivior $2.2B Merger Creates CNS Giant | Pharma and Biotech Daily 04.08.2026 5min

  Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into recent transformative events that are shaping this dynamic industry, from strategic mergers to groundbreaking drug approvals. Starting with the merger between Supernus Pharmaceuticals and Indivior Pharmaceuticals, this all-stock deal valued at $2.2 billion is set to create a powerhouse focused on central nervous system (CNS) disorders. By c...
• 
  Replimune's Breakthrough in Cancer Therapy | Pharma and Biotech Daily 03.08.2026 6min

  Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent weeks have been a whirlwind of activity in the pharmaceutical and biotech sectors, showcasing significant strides in scientific breakthroughs, regulatory advancements, and strategic industry maneuvers. Replimune's Vusolimogene Oderparepvec has emerged as a beacon of hope in the fight against advanced melanoma. This gene therapy, utilizing an oncolytic vi...
• 
  Johnson & Johnson's $785M CAR-T Deal & More | Pharma and Biotech Daily 31.07.2026 5min

  Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of events that underscore the dynamic nature of these industries, characterized by scientific advancements, strategic partnerships, and regulatory milestones. Johnson & Johnson has made headlines with its substantial $785 million upfront payment to Sail BioMed for an in vivo CAR-T cell therapy deal. This agreement includes an o...
• 
  Biogen Acquires Apellis for Growth | Pharma and Biotech Daily 30.07.2026 5min

  Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Biogen has made a significant acquisition by purchasing Apellis Pharmaceuticals, a move expected to boost its 2026 revenue guidance with promising growth prospects. This strategic acquisition, along with strong sales from new drugs, enhances Biogen's position in the competitive market for neurological disorders. By integrating Apellis' offerings, Biogen is pois...
• 
  GlaxoSmithKline's $2.5B Restructuring Near AstraZeneca | Pharma and Biotech Daily 29.07.2026 5min

  Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into the latest news shaping these dynamic sectors, exploring strategic corporate maneuvers, groundbreaking scientific advances, and pivotal regulatory changes. GlaxoSmithKline (GSK) is embarking on a comprehensive restructuring initiative aimed at achieving $2.5 billion in annual cost savings by 2029. This ambitious initiative underscores the co...
• 
  AstraZeneca's $80B Target Amid Setbacks? | Pharma and Biotech Daily 28.07.2026 4min

  Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a wealth of significant advancements and strategic moves shaping the industry landscape. AstraZeneca is making waves with its steadfast commitment to reaching an $80 billion revenue target by 2030. This ambitious goal is underpinned by strong sales in oncology and rare disease treatments, despite some setbacks with underperforming drugs...
• 
  Scribe Therapeutics Raises $129M in IPO | Pharma and Biotech Daily 27.07.2026 5min

  Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into the latest groundbreaking advancements, strategic corporate maneuvers, and pivotal regulatory updates shaping this dynamic industry landscape. Starting with some exciting news, Scribe Therapeutics has successfully closed its initial public offering, raising a significant $129 million. This substantial funding will drive forward their pi...
• 
  Eli Lilly's Retatrutide: 22.6% Weight Loss in Phase 3! | Pharma and Biotech Daily 24.07.2026 4min

  Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the most exciting scientific breakthroughs and regulatory developments that are shaping the future of healthcare. Eli Lilly's retatrutide, a promising small molecule GLP-1 receptor agonist, has achieved significant results in Phase 3 trials, leading to an impressive 22.6% weight loss in patients with obesity and cardiovascular d...
• 
  Repligen Buys BioLife for $1.5B | Pharma and Biotech Daily 23.07.2026 5min

  Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're delving into a series of significant breakthroughs and strategic moves reshaping the industry landscape. Repligen Corporation's recent decision to acquire BioLife Solutions for $1.5 billion marks a pivotal moment in the cell therapy sector. BioLife Solutions' expertise in cryopreservation media is integral to maintaining cell viability during stora...
• 
  Bristol Myers & NVIDIA's $1.5B AI Deal: Game Changer? | Pharma and Biotech Daily 22.07.2026 4min

  Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent advancements in these sectors highlight a fascinating intersection of technology and medicine, underscoring a push towards innovation that promises to reshape healthcare delivery. Bristol Myers Squibb has expanded its collaboration with NVIDIA, aiming to create what could become the most powerful AI infrastructure dedicated to life sciences. This partner...
• 
  Samsung Biologics' $1.8B Peptide Expansion | Pharma and Biotech Daily 21.07.2026 5min

  Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're navigating through a myriad of transformative advancements reshaping the industry. From artificial intelligence-driven research breakthroughs to strategic acquisitions in emerging therapeutic areas, these developments are setting new benchmarks in drug discovery and patient care. **Strategic Acquisitions and Expansions:** Samsung Biologics' recent ...